{
    "clinical_study": {
        "@rank": "161385", 
        "arm_group": [
            {
                "arm_group_label": "Recombinant Lactoferrin", 
                "arm_group_type": "Active Comparator", 
                "description": "Recombinant lactoferrin will be administered by mouth twice daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matched placebo will be administered by mouth twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin\n      (1500mg bid) for reducing inflammation among HIV positive participants."
        }, 
        "brief_title": "Lactoferrin Treatment in HIV Patients", 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. HIV-positive participants receiving ART for >1 year\n\n          2. HIV RNA level <200 copies/mL for at least 6 months (\u22652 separate values)\n\n          3. Age >40 years\n\n        Exclusion Criteria:\n\n          1. Prior cardiovascular disease or stroke\n\n          2. Diabetes\n\n          3. Rheumatologic Diseases\n\n          4. Pregnancy\n\n          5. Chronic kidney disease, stage IV or V (creatinine clearance <30 mL/min/1.73m2)\n\n          6. Cirrhosis or end-stage liver disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830595", 
            "org_study_id": "PCC-006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Recombinant Lactoferrin", 
                "intervention_name": "Recombinant Lactoferrin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55415"
                }, 
                "name": "Hennepin County Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients", 
        "other_outcome": [
            {
                "measure": "Monocyte Activation", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Tissue Factor Activity", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Self reported side effects", 
                "measure": "Tolerability", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Changes in markers of systemic inflammation (e.g., IL-6) and coagulation (e.g., D-dimer) will be compared between treatment groups", 
                "measure": "Inflammation and Coagulation", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830595"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Minneapolis Medical Research Foundation", 
            "investigator_full_name": "Jason Baker", 
            "investigator_title": "Associate Professor of Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "DAIDS criteria will be used for grading adverse events (serious and non-serious)", 
            "measure": "Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "3 Months"
        }, 
        "source": "Minneapolis Medical Research Foundation", 
        "sponsors": {
            "collaborator": {
                "agency": "Ventria Bioscience", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Jason Baker", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}